PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.9% - Time to Buy?

Key Points

• PTC shares rose 6.9% to $67.16 on Monday amid below-average volume, but the stock still trades under its 50‑day ($72.77) and 200‑day ($69.45) moving averages; analysts show a consensus Moderate Buy with an average price target of $82.79.
• The company posted a major earnings and revenue miss for the quarter—EPS ($1.67) vs. ($0.21) expected and revenue $164.7M vs. $281.5M consensus—revenue fell 22.7% year‑over‑year and analysts forecast -4.52 EPS for the fiscal year.
• Insiders have been net sellers (163,604 shares, ~$12.3M sold in the last 90 days) and analyst opinions are mixed—10 Buys, 4 Holds and 1 Sell—indicating divergent views on PTC’s near‑term outlook.

PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) shot up 6.9% on Monday . The company traded as high as $67.16 and last traded at $67.16. 794,270 shares traded hands during mid-day trading, a decline of 38% from the average session volume of 1,278,291 shares. The stock had previously closed at $62.82.

Wall Street Analysts Forecast Growth

PTCT has been the topic of several recent analyst reports. Wells Fargo & Company decreased their target price on PTC Therapeutics from $93.00 to $86.00 and set an "overweight" rating on the stock in a research note on Friday, February 20th. Morgan Stanley upped their target price on shares of PTC Therapeutics from $90.00 to $92.00 and gave the company an "overweight" rating in a research report on Monday, February 23rd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of PTC Therapeutics in a research note on Monday, December 29th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of PTC Therapeutics in a research report on Friday, February 20th. Finally, TD Cowen reaffirmed a "hold" rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $82.79.

PTC Therapeutics Price Performance

The business has a 50-day moving average of $72.77 and a two-hundred day moving average of $69.45. The company has a market cap of $5.63 billion, a P/E ratio of 8.78 and a beta of 0.51.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.67) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.46). The firm had revenue of $164.68 million during the quarter, compared to the consensus estimate of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The business's revenue for the quarter was down 22.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.85) earnings per share. Equities analysts anticipate that PTC Therapeutics, Inc. will post -4.52 EPS for the current fiscal year.

Insider Activity

In other PTC Therapeutics news, VP Mark Elliott Boulding sold 4,879 shares of the firm's stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $77.44, for a total value of $377,829.76. Following the completion of the sale, the vice president directly owned 117,659 shares in the company, valued at $9,111,512.96. This trade represents a 3.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Glenn Md Phd Steele, Jr. sold 12,000 shares of PTC Therapeutics stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $76.35, for a total transaction of $916,200.00. Following the completion of the transaction, the director directly owned 18,500 shares in the company, valued at $1,412,475. This represents a 39.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 163,604 shares of company stock worth $12,289,056. Insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

A number of institutional investors have recently made changes to their positions in the business. UMB Bank n.a. acquired a new position in PTC Therapeutics during the 4th quarter valued at about $26,000. Smartleaf Asset Management LLC grew its stake in shares of PTC Therapeutics by 101.3% during the third quarter. Smartleaf Asset Management LLC now owns 469 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 236 shares during the last quarter. Optiver Holding B.V. grew its stake in shares of PTC Therapeutics by 96.5% during the third quarter. Optiver Holding B.V. now owns 507 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 249 shares during the last quarter. Comerica Bank increased its holdings in shares of PTC Therapeutics by 868.5% during the third quarter. Comerica Bank now owns 523 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 469 shares in the last quarter. Finally, Salomon & Ludwin LLC acquired a new position in shares of PTC Therapeutics during the fourth quarter valued at about $41,000.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.